Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2015, Article ID 874054, 10 pages
Research Article

Bone Marrow Stromal Antigen 2 Is a Novel Plasma Biomarker and Prognosticator for Colorectal Carcinoma: A Secretome-Based Verification Study

1Division of Colon and Rectal Surgery, Chang Gung Memorial Hospital, Linkou, Taiwan
2Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University, Taoyuan 333, Taiwan
3Department of Cell and Molecular Biology, College of Medicine, Chang Gung University, Taoyuan 333, Taiwan
4Molecular Medicine Research Center, Chang Gung University, Taoyuan 333, Taiwan
5Chang Gung University College of Medicine, Linkou, Taiwan
6Department of Public Health, Chang Gung University, Taoyuan 333, Taiwan
7Pathology Core of the Chang Gung Molecular Medicine Research Center, Taoyuan 333, Taiwan

Received 2 March 2015; Accepted 22 June 2015

Academic Editor: Bryan C. Fuchs

Copyright © 2015 Sum-Fu Chiang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Supplementary Material

Supplementary materials provide some extra information about category setting, clinicopathologic features of CRC patients, and mean plasma level of BST2 according to tumor stage. BST2 did not show its defference among different stages. These materials were not included in the maintext, however, they were still important in our research. Supplementary Table 1 showed our priority of candidates validation. Six criterias were used, including two large databases, HPA and HPPP. Secretome based verification is a tremendous work, and these supplementary materials showed details of our strategy.

  1. Supplementary Material